Evidence map›Paper›PMID 38938072›Full record

ArticleMolecular genetics & genomic medicine2024

Unexpected complexity in the molecular diagnosis of spastic paraplegia 11.

Irene Mademont-Soler, Susanna Esteba-Castillo, Aida Jiménez-Xifra, Berta Alemany, Núria Ribas-Vidal, Maria Cutillas, Mònica Coll, Mel Lina Pinsach, Sara Pagans, Mireia Alcalde and 7 more

Abstract readCase Reports
In one paragraph

Article in Molecular genetics & genomic medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Irene Mademont-SolerÀrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.
Susanna Esteba-CastilloGrup de Trastorns del Neurodesenvolupament, Institut Investigació Biomèdica de Girona, Girona, Spain.
Aida Jiménez-XifraDepartament de Citogenètica, Reference Laboratory, Barcelona, Spain.
Berta AlemanyServei de Neurologia, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain.
Núria Ribas-VidalGrup de Trastorns del Neurodesenvolupament, Institut Investigació Biomèdica de Girona, Girona, Spain.
Maria CutillasÀrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.
Mònica CollUnitat de Genòmica i Medicina Personalitzada, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.
Mel Lina PinsachUnitat de Genòmica i Medicina Personalitzada, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.
Sara PagansGrup de Genètica Cardiovascular, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Girona, Spain.
Mireia AlcaldeGrup de Genètica Cardiovascular, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta, Girona, Spain.
Marina Viñas-JornetDepartament de Genètica Molecular, qGenomics, Barcelona, Spain.
Mercedes Montero-ValeDepartament de Genètica Molecular, qGenomics, Barcelona, Spain.
Marta de Castro-MiróDepartament de Genètica Molecular, qGenomics, Barcelona, Spain.
Jairo RodríguezDepartament de Genètica Molecular, qGenomics, Barcelona, Spain.
Lluís ArmengolDepartament de Genètica Molecular, qGenomics, Barcelona, Spain.
Xavier QueraltÀrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.
María ObónÀrea de Genètica Clínica i Consell Genètic, Laboratori Clínic Territorial Girona, Institut Català de la Salut, Girona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSpastic paraplegia 11 (SPG11) is the most prevalent form of autosomal recessive hereditary spastic paraplegia, resulting from biallelic pathogenic variants in the SPG11 gene (MIM *610844).

methodsThe proband is a 36-year-old female referred for genetic evaluation due to cognitive dysfunction, gait impairment, and corpus callosum atrophy (brain MRI was normal at 25-years-old). Diagnostic approaches included CGH array, next-generation sequencing, and whole transcriptome sequencing.

resultsCGH array revealed a 180 kb deletion located upstream of SPG11. Sequencing of SPG11 uncovered two rare single nucleotide variants: the novel variant c.3143C>T in exon 17 (in cis with the deletion), and the previously reported pathogenic variant c.6409C>T in exon 34 (in trans). Whole transcriptome sequencing revealed that the variant c.3143C>T caused exon 17 skipping.

conclusionWe report a novel sequence variant in the SPG11 gene resulting in exon 17 skipping, which, along with a nonsense variant, causes Spastic Paraplegia 11 in our proband. In addition, a deletion upstream of SPG11 was identified in the patient, whose implication in the phenotype remains uncertain. Nonetheless, the deletion apparently affects cis-regulatory elements of the gene, suggesting a potential new pathogenic mechanism underlying the disease in a subset of undiagnosed patients. Our findings further support the hypothesis that the origin of thin corpus callosum in patients with SPG11 is of progressive nature.

Indexed as

Spastic Paraplegia, HereditaryAdultCodon, NonsenseCorpus CallosumExonsFemaleHumansPhenotypeProteinsSequence DeletionCodon, NonsenseProteinsSPG11 protein, humancis‐regulatory elementsgenetic diagnosisspastic paraplegia 11SPG11whole transcriptome sequencing

Identifiers

PMID38938072
PMCPMC11211614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.